U.S. Markets closed

Teva Pharmaceutical Industries Limited (TEVA)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
32.61+0.09 (+0.28%)
At close: 4:02PM EDT
People also watch
Full screen
Previous Close32.52
Bid0.00 x
Ask0.00 x
Day's Range32.30 - 32.81
52 Week Range27.60 - 56.44
Avg. Volume7,554,876
Market Cap33.13B
PE Ratio (TTM)418.08
Earnings DateN/A
Dividend & Yield1.36 (4.38%)
Ex-Dividend Date2017-06-01
1y Target EstN/A
Trade prices are not sourced from all markets
  • Forbes3 hours ago

    Facebook, Baidu, Coach And 5 Other Blue-Chip Stocks To Buy For Second-Half 2017

    The bull market that kicked off in March 2009 should be on the front cover of AARP magazine. At age 8, the S&P 500 bull run is very old and very overvalued compared to its historical ratios. Given the less than stellar circumstances, how should you invest now?

  • Glaxo's (GSK) Shingles Candidate Phase III Data Positive
    Zacks2 days ago

    Glaxo's (GSK) Shingles Candidate Phase III Data Positive

    GlaxoSmithKline plc (GSK) announced positive top-line results from a phase III revaccination study on its shingles vaccine candidate, Shingrix, in older patients.

  • Reuters3 days ago

    GSK wins $235 million from Teva in Coreg patent trial

    A U.S. jury has ordered Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent covering its blood pressure drug Coreg, court documents showed. A federal jury in Wilmington, Delaware on Tuesday found that Teva willfully infringed the patent in connection with its sales of a generic version of the drug with a label indicating it could be used for treating chronic heart failure. The jury rejected Teva's contention that the patent was invalid.